GAMMA Investing LLC Boosts Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

GAMMA Investing LLC lifted its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 8,947.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 17,552 shares of the specialty pharmaceutical company’s stock after buying an additional 17,358 shares during the period. GAMMA Investing LLC owned about 0.05% of Collegium Pharmaceutical worth $524,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. New Age Alpha Advisors LLC acquired a new stake in Collegium Pharmaceutical during the 4th quarter valued at $40,000. Virtus Fund Advisers LLC boosted its holdings in Collegium Pharmaceutical by 30.5% in the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 565 shares during the last quarter. FORA Capital LLC acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter worth about $223,000. Aigen Investment Management LP acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter worth about $230,000. Finally, Summit Global Investments purchased a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth about $232,000.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $29.60 on Thursday. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29. The stock has a fifty day moving average of $28.40 and a 200-day moving average of $29.55. The company has a market capitalization of $951.05 million, a PE ratio of 24.26 and a beta of 0.63. The company has a debt-to-equity ratio of 3.30, a quick ratio of 1.01 and a current ratio of 1.08.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). The business had revenue of $177.76 million during the quarter, compared to analysts’ expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 6.61% and a return on equity of 99.08%. Collegium Pharmaceutical’s revenue for the quarter was up 22.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.45 EPS. As a group, equities analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on COLL shares. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a research report on Friday, May 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a report on Wednesday, April 9th. Wall Street Zen lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 19th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $43.75.

Insider Buying and Selling at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $30.62, for a total transaction of $202,122.62. Following the transaction, the director now directly owns 70,658 shares of the company’s stock, valued at $2,163,547.96. This represents a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.